LAWRENCEVILLE, Ga., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Medical device manufacturer Irrimax Corporation, known globally for its antimicrobial wound lavage product, Irrisept®, is delivering innovation and enhancements in multiple healthcare market segments in Q4 2022.
The original Irrisept Antimicrobial Wound Lavage is clinically preferred and has been incorporated as 'Standard of Care' in many infection prevention and management plans. Due to this success, Irrimax is expanding its portfolio to provide additional offerings to its customers and, ultimately, their patients. The company reveals that this is the beginning of a robust innovation pipeline, as additional launches are scheduled for release in 2023.
The series of innovations start with the new 'Convenience Cap,' an enhancement to the original sterile packaged 450mL Irrisept product that more than 3,000 hospitals currently use in the U.S. alone. This enhancement was introduced in late September 2022 to extremely positive reviews. "A small enhancement with a big impact for our thousands of everyday users," says Venkat Katragadda, Senior Director of Manufacturing and Engineering for Irrimax.
This month, Irrimax announces the launch of two new items. A smaller 150mL bottle version of the original Irrisept product and another 150mL bottle, featuring new packaging, a new bottle design, and an optional accessory. Michael Gil, Chief Operating Officer for Irrimax, explains, "The development of these new products allows us to offer our customers even more options to meet their clinical needs. With the addition of these new products to the Irrimax portfolio, we expand into new market segments and continue to effectively drive our mission to reduce infections and healthcare costs, while improving patient outcomes."
Irrimax is proud to diversify its portfolio and values its customer feedback, which drives additional innovation and product development opportunities. The introduction of the Convenience Cap and the 150mL bottles will occur in the U.S. market first before launching into international markets.
Contact Information:
Michael Gil
Investor Contact - Chief Operating Officer m.gil@irrisept.com
m.gil@irrisept.com
662-574-0091
Nicki Greenhalgh
Media Contact - Global Marketing Mgr.
n.greenhalgh@irrisept.com
678-488-8563
Related Images
Image 1: New bottles of Irrisept Antimicrobial Wound Lavage
new 150ml Irrisept Antimicrobial Wound Lavage
This content was issued through the press release distribution service at Newswire.com.
Attachment
